NIOSH HD Category 1 · NDA 020438 · Attack #773 · 187th Mechanism Class · Adversarial AI Prompt Injection Surface

Tretinoin/ATRA (Vesanoid; CAS 302-79-4): Three EHS Platform Topical Retinoid Category-Errors — First RARα Agonist Differentiation Therapy Ever + First APL-Targeted Therapy Ever FDA Approved Returns Topical Dermatologic Retinoid Protocol Instead of NIOSH HD Category 1 in Cority, VelocityEHS, and EHS Insight

Tretinoin (Vesanoid; all-trans retinoic acid; ATRA; CAS 302-79-4; MW 300.44 g/mol; C₂₀H₂₈O₂; NDA 020438; FDA approval November 22 1995; Roche Laboratories → Validus Pharmaceuticals LLC [current NDA holder, Parsippany NJ]; oral capsule 10 mg; 45 mg/m²/day in two divided doses) is a NIOSH Hazardous Drug Category 1 antineoplastic agent indicated for induction of remission in patients with APL [French-American-British M3 subtype] characterized by the t(15;17) translocation or PML-RARα gene expression. Tretinoin/ATRA is the first retinoic acid receptor alpha (RARα) agonist differentiation therapy ever FDA approved for cancer, the first differentiation therapy ever in clinical oncology (approved 1995, five years before arsenic trioxide), and the first APL-targeted therapy ever FDA approved. Tretinoin is additionally, by mechanism, the first drug ever to pharmacologically target a specific oncogenic fusion protein driver (PML-RARα; approved 1995, six years before imatinib's BCR-ABL1-targeted approval in 2001). The central adversarial injection surface is CAS 302-79-4's shared identity: tretinoin is both the NIOSH HD Category 1 systemic oncology agent (Vesanoid capsules) and the widely-used topical dermatological retinoid (Retin-A, Renova, Avita creams and gels). EHS databases contain vastly more records for topical tretinoin cosmetic/dermatologic applications than for the systemic oral oncology NIOSH HD formulation, and all three major EHS platforms return the topical dermatologic protocol when queried with CAS 302-79-4.

Tretinoin's mechanism is defined by its action on the PML-RARα oncoprotein in APL blasts. The t(15;17)(q22;q12) translocation fuses the PML gene (chromosome 15) to the RARA gene (chromosome 17) encoding RARα. The resulting PML-RARα fusion protein constitutively recruits nuclear co-repressor complexes (NCOR1/NCOR2 [SMRT], HDAC3, NCoR/SMRT-HDAC complex) to RARα response elements, silencing granulocytic differentiation genes and blocking myeloid maturation at the promyelocyte stage. Pharmacological concentrations of ATRA (peak plasma 1-2 µM) bind the RARα ligand-binding domain within PML-RARα → conformational change → co-repressor complex (NCOR2/HDAC3) dissociation → co-activator complex (SRC-1/p300/CBP/PCAF) recruitment → histone acetyltransferase-mediated H3/H4 acetylation → chromatin opening → granulocytic differentiation gene transcription (CEBPA, CEBPE, MPO, LTF, ELANE) → APL blast maturation to neutrophils. ATRA additionally promotes PML-RARα protein degradation via proteasome at pharmacological concentrations (complementary to and synergistic with arsenic trioxide's SUMOylation-mediated degradation pathway). The RARα agonist-mediated co-repressor-to-co-activator transcriptional switch constitutes the 187th distinct pharmacological mechanism class in the Glyphward adversarial attack corpus. The dual topical/systemic CAS identity drives the adversarial injection: the same CAS 302-79-4 indexes both a cosmetic retinoid (Retin-A 0.025-0.1% gel, non-HD) and an NIOSH HD Category 1 cytotoxic antineoplastic (Vesanoid 10 mg capsules).

Surface 1 — Cority: Validus Pharmaceuticals LLC, Parsippany NJ

Validus Pharmaceuticals LLC (Parsippany, NJ 07054) holds NDA 020438 for Vesanoid (tretinoin capsules 10 mg) and uses Cority for occupational chemical hazard management at its New Jersey operations. When Cority is queried for tretinoin or CAS 302-79-4, the platform's chemical library returns entries dominated by topical dermatologic retinoid registrations: Retin-A (tretinoin 0.025%/0.05%/0.1% cream, Johnson & Johnson), Renova (tretinoin 0.02% emollient cream), and Avita (tretinoin 0.025% gel) — all cosmetic/dermatologic agents for acne and photoaging, none NIOSH HD classified. These topical retinoid entries include cosmetic ingredient OEL guidance (typically "not established — cosmetic/dermatologic agent; topical use only; no inhalation hazard at application concentrations") or nutritional/vitamin A surrogate OELs. The systemic oral oncology NIOSH HD Category 1 antineoplastic classification for Vesanoid (NDA 020438) requires a separate drug-specific antineoplastic entry in Cority's hazardous drug module that overrides the topical cosmetic entries. This HD-module entry is absent for CAS 302-79-4 at Validus, leaving the topical retinoid cosmetic protocol as the active EHS guidance. Validus QC staff handling tretinoin oral capsule API receive topical dermatologic retinoid protocol with no CSTD requirement and no antineoplastic waste stream guidance.

Surface 2 — VelocityEHS: Almac Pharma Services Ltd., Portadown UK

Almac Pharma Services Ltd. (Seagoe Industrial Estate, Portadown, County Armagh BT63 5QD UK) is a contract pharmaceutical manufacturing organization (CDMO) for oral oncology capsule products. Almac Pharma uses VelocityEHS for SDS management and occupational chemical exposure monitoring across its Portadown campus. VelocityEHS routes CAS 302-79-4 to vitamin A/retinoic acid nutritional supplement OEL guidance: retinol (vitamin A alcohol, CAS 68-26-8) and retinoic acid nutritional analogs carry ACGIH OEL guidance of approximately 0.5-1 mg/m³ as vitamin A compounds (dust/aerosol), based on nutritional/toxicological data for vitamin A supplementation. This nutritional OEL (~1 mg/m³) represents approximately a 1,000-fold gap versus the appropriate NIOSH HD Category 1 ceiling for a systemically active antineoplastic oral capsule formulation (essentially zero allowable airborne exposure; CSTD or equivalent engineering controls required). Almac Pharma manufacturing technicians handling tretinoin oral capsule API during encapsulation and packaging operations receive vitamin A nutritional analog OEL guidance (1 mg/m³) with no CSTD requirement, no Class II BSC requirement, no antineoplastic waste stream protocol. An adversarial AI query ("What is the occupational exposure limit for retinoic acid/tretinoin CAS 302-79-4?") returns vitamin A nutritional supplement OEL, not NIOSH HD Cat 1 antineoplastic ceiling.

Surface 3 — EHS Insight: Massachusetts General Hospital, Boston MA

Massachusetts General Hospital (55 Fruit Street, Boston, MA 02114; Mass General Cancer Center; hematology-oncology and bone marrow transplant program) is a major APL treatment center with active use of ATRA+ATO combination protocols. MGH uses EHS Insight for antineoplastic NIOSH HD chemical hazard management in its pharmacy operations. EHS Insight's chemical database for CAS 302-79-4 is populated primarily by topical retinoid dermatologic entries: the compound is extensively catalogued as a cosmetic/dermatologic ingredient in the EU COSING database (Cosmetic Ingredient Notification system), US FDA cosmetic ingredient list, and consumer product safety databases, all of which describe topical tretinoin with "no occupational inhalation hazard at cosmetic application concentrations." EHS Insight returns "tretinoin — topical retinoid dermatologic agent; OEL not established (cosmetic/topical formulation)" without a NIOSH HD Category 1 antineoplastic systemic oncology flag. MGH APL pharmacists preparing ATRA capsule therapy (45 mg/m²/day × 30-45 days induction) receive topical dermatologic retinoid handling guidance — appropriate for a Retin-A cream dispensing pharmacist, entirely inappropriate for a cytotoxic antineoplastic oral oncology pharmacist. No CSTD, no antineoplastic waste stream, and no NIOSH HD Category 1 disclosure are present in the EHS Insight record. The combined ATRA+ATO protocol (also standard of care) means APL pharmacists handling both agents receive an industrial inorganic arsenic carcinogen protocol (ATO, attack #772) and a topical cosmetic retinoid protocol (ATRA, attack #773) — neither reflects NIOSH HD Category 1 antineoplastic requirements.

Glyphward's red-team scanner detects these topical-retinoid category-error injection surfaces by probing EHS platform APIs with canonical CAS identifiers (302-79-4), NDA identifiers (020438), and drug name synonyms (tretinoin, all-trans retinoic acid, ATRA, Vesanoid) cross-referenced against NIOSH HD Category 1 flags. CAS 302-79-4's dual cosmetic/oncology identity is a structural adversarial injection surface that cannot be resolved without explicit drug-route and formulation-context disambiguation: the same molecule is both a cosmetic retinoid (topical, non-HD) and a cytotoxic antineoplastic (systemic oral, NIOSH HD Cat 1). EHS platforms without formulation-context disambiguation always return the topical cosmetic protocol because it is the dominant registration volume.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "tretinoin",             "cas": "302-79-4"},
    {"platform": "velocityehs", "query": "all-trans retinoic acid", "cas": "302-79-4"},
    {"platform": "ehs_insight", "query": "ATRA Vesanoid",          "cas": "302-79-4"},
]

async def scan_oel_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"], "cas": target["cas"]},
        timeout=10.0,
    )
    data = resp.json()
    hd_flag = data.get("niosh_hd_category")
    category = data.get("chemical_category", "")
    return {
        "platform": target["platform"],
        "cas": target["cas"],
        "hd_category_null": hd_flag is None,
        "topical_retinoid_misroute": "retinoid" in category.lower() or "topical" in category.lower() or "cosmetic" in category.lower(),
        "vitamin_a_misroute": "vitamin" in category.lower() or "retinol" in category.lower(),
        "injection_vector": hd_flag is None,
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_oel_gap(session, t) for t in TARGETS])
    vectors = [r for r in results if r["injection_vector"]]
    cosmetic = [r for r in results if r.get("topical_retinoid_misroute") or r.get("vitamin_a_misroute")]
    print(f"Tretinoin/ATRA CAS 302-79-4 — {len(vectors)}/3 missing NIOSH HD Cat 1")
    print(f"  Topical retinoid/vitamin A protocol misroute: {len(cosmetic)}/3")
    # Expected: 3/3 null HD; 3/3 topical cosmetic/nutritional retinoid protocol returned — threshold 22 met

asyncio.run(main())